VSAnadian health officials said on Monday they would stop offering AstraZeneca’s vaccine to people under the age of 55 and demand a new analysis of the risks and benefits of the vaccine based on age and gender.
These movements follow reports from Europe of rare but serious blood clots, bleeding and in some cases of death after vaccination, mainly in young women. No such case has been reported in Canada, with approximately 307,000 doses of AstraZeneca administered.
The National Advisory Council on Immunization, a group of independent experts, said on Monday that the rate at which the bleeding complication was occurring was not yet clear. So far, 40% of people who have developed it have died, but that could decrease as more cases are identified and treated early, he said.
“From what is currently known, there is substantial uncertainty about the benefits of administering the AstraZeneca Covid-19 vaccine to adults under the age of 55,” the council said in a recommendation written.